Feb 6 (Reuters) - Medical equipment maker Mettler-Toledo International MTD.N forecast annual profit above estimates on Thursday, banking on strong demand for its laboratory instruments used in drug development.
The company had said in November that market conditions remain soft, especially in China, but added that it expects them to gradually improve throughout 2025.
Some analysts are hopeful that a recent interest rate cut by the Federal Reserve could improve funding for small- and medium-sized biotechs, as borrowing costs might ease and boost demand.
The Columbus, Ohio-based company forecast 2025 adjusted profit in the range of $42.35 to $43.00 per share, compared to analysts' estimates of $42.13 per share, as per data compiled by LSEG.
Mettler-Toledo said its profit forecast includes headwinds from shipping delays and a stronger dollar.
The firm's fourth-quarter sales rose 12% to $1.05 billion, beating estimates of $1.01 billion.
On an adjusted basis, Mettler-Toledo earned a profit of $12.41 per share for the quarter ending December 31, topping analysts' estimates of $11.71 each.
The company had also said that it would benefit from the prior-year shipping delays in the fourth quarter.
(Reporting by Christy Santhosh and Sneha S K in Bengaluru; Editing by Alan Barona)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。